As part of our series focussing on available medicines in Australia, we have added a product review of the use of inotuzumab ozogamicin in treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia.
This review discusses inotuzumab ozogamicin indications and dosage, contraindications and a series of clinical studies featuring its use. It also provides commentary and recommendations from Dr Ashish Bajel, a haematologist and BMT physician at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital.
Please login below to download this issue (PDF)